Everwest Real Estate Partners
Director of Portfolio Management
Everwest Real Estate Investors
Director of Portfolio Management
Kroger Sep 2011 - Jul 2013
Real Estate Specialist - Mid-Atlantic Marketing Area
Kroger Aug 2008 - Aug 2011
Financial Analyst - Capital Management Department
Kroger Mar 2006 - Jul 2008
Internal Auditor
Education:
University of Wisconsin - Madison 2013 - 2015
Master of Business Administration, Masters, Real Estate
Gies College of Business - University of Illinois Urbana - Champaign 2001 - 2005
Bachelors, Bachelor of Science, Finance
Universidade De São Paulo 2004 - 2004
Skills:
Financial Analysis Financial Modeling Real Estate Capital Projects Commercial Real Estate Analysis Real Estate Development Real Estate Project Management Negotiating Leases Real Estate Due Diligence Project Entitlements Dcf Pro Forma Development Acquisition Analysis Real Estate Finance Sensitivity Analysis Strategic Planning Retail Site Selection New Markets Tax Credits Management Accounting Real Estate Economics Leases Finance
Needham analyst Chad Messer cut his 2017Exondys 51 sales expectations to $109 million from $183 million.He also lowered his price target on Sarepta stock to 75 from 78, though kept his outperform rating.
Date: Mar 01, 2017
Category: Business
Source: Google
Bevy Of Biotech Stocks Healthy; Sarepta, Bluebird, Exelixis Soar
The exit of the FDA staff member, Dr. Ron Farkas, is a plus for the Sarepta drug, but not the biggest plus, Needham analyst Chad Messer said in a research note Wednesday, in which he hiked his price target on Sarepta stock to 47 from 26. Farkas "was notthe only skeptic and frankly we do not believ
Date: Sep 14, 2016
Category: Business
Source: Google
Esperion Therapeutics Inc Bolts Higher As Cholesterol Drug Aces Mid-Stage Study
According to Needham & Co analyst Chad Messer, ETC-1002 stands a better chance of being used in conjunction with statins, rather than as a separate treatment. This brings the drug's market to around 10 million patients 30% of the 35 million patients who didnt respond well to statin treatment.
makers have been developing the ETC -1002 as an additional therapy to statins or an alternative for those who are intolerant to statins. Needham & Co analyst Chad Messer informed that instead of replacing statins altogether he is expecting the drug to be adopted quicker as an additional therapy.
Date: Mar 18, 2015
Category: Health
Source: Google
Data shows Sarepta's muscular dystrophy treatment is effective
While the company, Sarepta Therapeutics, hailed the results as positive, they apparently were not positive enough for investors, who dumped the stock when markets opened. Chad Messer, an analyst with Needham & Co LLC, a New York investment firm, said he was puzzled by the markets reaction.